SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling

Journal of Autoimmunity

Volumn 42, Issue , 2013, Pages 117-129

  Gardner, Peter J ^a   Joshi, Lavnish ^a   Lee, Richard W J ^a,b   Dick, Andrew D ^a,b   Adamson, Peter ^c   Calder, Virginia L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Beh et's; EAU; HDAC; SIRT1; STAT5A B; Uveitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; SIRTUIN 1; SRT 2379; STAT5A PROTEIN; STAT5B PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UVEORETINITIS;

ADMINISTRATION, ORAL; ANIMALS; BEHCET SYNDROME; CELL GROWTH PROCESSES; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; EYE; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION MEDIATORS; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; SIGNAL TRANSDUCTION; SIRTUIN 1; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84877134225     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.01.011     Document Type: Article

References (52)

1. Smith K.T., Workman J.L. Introducing the acetylome. Nature Biotechnology 2009, 27:917-919.
2. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
3. Sauve A.A., Wolberger C., Schramm V.L., Boeke J.D. The biochemistry of sirtuins. Annual Review of Biochemistry 2006, 75:435-465. Palo Alto: Annual Reviews.
4. Huang H., Tindall D.J. Dynamic FoxO transcription factors. Journal of Cell Science 2007, 120:2479-2487.
5. Dai H., Kustigian L., Carney D., Case A., Considine T., Hubbard B.P., et al. SIRT1 activation by small molecules. Journal of Biological Chemistry 2010, 285:32695-32703.
6. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annual Review of Pathology 2010, 5:253-295. Palo Alto: Annual Reviews.
7. Baur J.A. Resveratrol, sirtuins, and the promise of a DR mimetic. Mechanisms of Ageing and Development 2010, 131:261-269.
8. Kong S., McBurney M.W., Fang D. Sirtuin 1 in immune regulation and autoimmunity. Immunology and Cell Biology 2012, 90:6-13.
9. Chen L.-f., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO Journal 2002, 21:6539-6548.
10. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal 2004, 23:2369-2380.
11. Yang S.-R., Wright J., Bauter M., Seweryniak K., Kode A., Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-κB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. American Journal of Physiology. Lung Cellular and Molecular Physiology 2007, 292:L567-L576.
12. Zhang J., Lee S.-M., Shannon S., Gao B., Chen W., Chen A., et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. The Journal of Clinical Investigation 2009, 119:3048-3058.
13. Sequeira J., Boily G., Bazinet S., Saliba S., He X., Jardine K., et al. sirt1-null mice develop an autoimmune-like condition. Experimental Cell Research 2008, 314:3069-3074.
14. Gao B., Kong Q., Kemp K., Zhao Y.-S., Fang D. Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:899-904.
15. Gao X., Xu Y.X., Janakiraman N., Chapman R.A., Gautam S.C. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochemical Pharmacology 2001, 62:1299-1308.
16. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Molecular Pharmacology 2007, 72:1508-1521.
17. + cells, and decreased macrophage IL-6 expression. International Immunopharmacology 2009, 9:134-143.
18. Chen J., Zhou Y., Mueller-Steiner S., Chen L.-F., Kwon H., Yi S., et al. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. Journal of Biological Chemistry 2005, 280:40364-40374.
19. Alarcón de la Lastra C., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Molecular Nutrition & Food Research 2005, 49:405-430.
20. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
21. Caspi R.R., Stiff L.R., Morawetz R., Miller-Rivero N.E., Chan C.-C., Wiggert B., et al. Cytokine-dependent modulation of oral tolerance in a murine model of autoimmune uveitis. Annals of the New York Academy of Sciences 1996, 778:315-324.
22. Kerr E.C., Raveney B.J.E., Copland D.A., Dick A.D., Nicholson L.B. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. Journal of Autoimmunity 2008, 31:354-361.
23. Rao N.A., Kimoto T., Zamir E., Giri R., Wang R., Ito S., et al. Pathogenic role of retinal microglia in experimental uveoretinitis. Investigative Ophthalmology & Visual Science 2003, 44:22-31.
24. Takeuchi M., Hokama H., Tsukahara R., Kezuka T., Goto H., Sakai J., et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefe's Archive for Clinical and Experimental Ophthalmology/Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2005, 243:1147-1152.
25. Guenane H., Hartani D., Chachoua L., Lahlou-Boukoffa O.S., Mazari F., Touil-Boukoffa C. Production of Th1/Th2 cytokines and nitric oxide in Behçet's uveitis and idiopathic uveitis. Journal français d'ophtalmologie 2006, 29:146-152.
26. Chi W., Zhu X., Yang P., Liu X., Lin X., Zhou H., et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Investigative Ophthalmology & Visual Science 2008, 49:3058-3064.
27. LeHoang P. The gold standard of noninfectious uveitis: corticosteroids. Developments in Ophthalmology 2012, 51:7-28.
28. Beier U.H., Wang L., Bhatti T.R., Liu Y., Han R., Ge G., et al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Molecular and Cellular Biology 2011, 31:1022-1029.
29. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999, 10:249-259.
30. Crispi S., Sanzari E., Monfregola J., De Felice N., Fimiani G., Ambrosio R., et al. Characterization of the human STAT5A and STAT5B promoters: evidence of a positive and negative mechanism of transcriptional regulation. FEBS Letters 2004, 562:27-34.
31. Shen Q., Zhang Y., Uray I.P., Hill J.L., Kim H.-T., Lu C., et al. The AP-1 transcription factor regulates postnatal mammary gland development. Developmental Biology 2006, 295:589-603.
32. Miyazaki R., Ichiki T., Hashimoto T., Inanaga K., Imayama I., Sadoshima J., et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1263-1269.
33. Yang H., Zhang W., Pan H., Feldser H.G., Lainez E., Miller C., et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS ONE 2012, 7:e46364.
34. Beier U.H., Wang L., Han R., Akimova T., Liu Y., Hancock W.W. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Science Signalling 2012, 5:ra45.
35. Egwuagu C.E., Sztein J., Mahdi R.M., Li W., Chao-Chan C., Smith J.A., et al. IFN-γ increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. The Journal of Immunology 1999, 162:510-517.
36. + interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Investigative Ophthalmology & Visual Science 2007, 48:4153-4161.
37. Yoshimura T., Sonoda K.-H., Ohguro N., Ohsugi Y., Ishibashi T., Cua D.J., et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 2009, 48:347-354.
38. Nagata K., Maruyama K., Uno K., Shinomiya K., Yoneda K., Hamuro J., et al. Simultaneous analysis of multiple cytokines in the vitreous of patients with sarcoid uveitis. Investigative Ophthalmology & Visual Science 2012, 53:3827-3833.
39. Amadi-Obi A., Yu C.-R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nature Medicine 2007, 13:711-718.
40. Watson C., Whittaker S., Smith N., Vora A.J., Dumonde D.C., Brown K.A. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clinical & Experimental Immunology 1996, 105:112-119.
41. Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology 2006, 2:619-626.
42. Perez V., Papaliodis G., Chu D., Anzaar F., Christen W., Foster C. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocular Immunology and Inflammation 2004, 12:205-214.
43. Curnow S.J., Falciani F., Durrani O.M., Cheung C.M.G., Ross E.J., Wloka K., et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Investigative Ophthalmology & Visual Science 2005, 46:4251-4259.
44. Hohki S., Ohguro N., Haruta H., Nakai K., Terabe F., Serada S., et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Experimental Eye Research 2010, 91:162-170.
45. Kolls J.K., Lindén A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
46. Sestito R., Madonna S., Scarponi C., Cianfarani F., Failla C.M., Cavani A., et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. The FASEB Journal 2011, 25:916-927.
47. Matthews K., Wilkinson K.A., Kalsdorf B., Roberts T., Diacon A., Walzl G., et al. Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosis. Tuberculosis 2011, 91:587-593.
48. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969-984.
49. + APCs suppress experimental autoimmune uveitis. The Journal of Immunology 2011, 187:2130-2139.
50. Mastelic B., Freitas do Rosario A.P., Veldhoen M., Renauld J.-C., Jarra W., Sponaas A.-M., et al. IL-22 protects against liver pathology and lethality of an experimental blood-stage malaria infection. Frontiers in Immunology 2012, 3:85.
51. Rizzo L.V., Xu H., Chan C.C., Wiggert B., Caspi R.R. IL-10 has a protective role in experimental autoimmune uveoretinitis. International Immunology 1998, 10:807-814.
52. Agarwal R.K., Horai R., Viley A.M., Silver P.B., Grajewski R.S., Bo Su S., et al. Abrogation of anti-retinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms. The Journal of Immunology 2008, 180:5423-5429.